



Divi's Laboratories Limited

Date: December 05, 2024

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051
Stock Code: DIVISLAB

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001
Stock Code: 532488

Dear Sir/ Madam,

Sub: Clarification /Confirmation on news item appearing in “Media/Publication” under Regulation 30 of SEBI (LODR) Regulations, 2015

Ref: NSE Letter vide NSE/CM/Surveillance/15036 dated December 05, 2024; and BSE email vide L/SURV/ONL/RV/SM/ (2024-2025)/ 125 dated December 05, 2024

This is with reference to recent news item which appeared in the “Website-www.moneycontrol.com” dated December 05, 2024 captioned “Divi's Labs shares fall nearly 3% as US court says Novartis cannot block generic of best-selling heart drug”.

We hereby clarify that we can not comment on the patent lawsuits of big pharma companies and its impact on them.

As a Contract Manufacturing Organization (CDMO) and manufacturer of Active Pharmaceutical Ingredients (APIs), in the normal course of our business, we have supply agreements with some of our customers.

There is no material impact of this news article on our Company.

Further, in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information and records.

Yours faithfully,
For Divi's Laboratories Limited

M. Satish Choudhury
Company Secretary & Compliance Officer